Publicaciones en las que colabora con Antonio González Martín (8)

2018

  1. Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2018), 20, 3, (274-285), 10.1007/s12094-017-1719-x)

    Clinical and Translational Oncology

  2. Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia

  3. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 274-285

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

2016

  1. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

    Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308

2013

  1. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

    Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525

2012

  1. Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

    Annals of Oncology, Vol. 23, Núm. 3, pp. 625-631

2009

  1. Guidelines for HER2 testing in breast cancer: A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 11, Núm. 6, pp. 363-375